Blood test to guide extra stomach or esophagus cancer treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stomach, gastroesophageal junction, or lower esophagus adenocarcinoma with HER2-positive tumor results
- After surgery, your ctDNA blood test (Signatera) must be positive
- You had chemotherapy before surgery for at least 6 weeks, then surgery removed the tumor completely with clear margins (R0)
- A scan after surgery must show no spread to other organs (no metastases)
- Your heart and organ tests must meet safety thresholds (including LVEF at least 50%) and you must be well enough for treatment (ECOG 0–1)
- You must not have had prior HER2-targeted therapy such as trastuzumab, and you must have recovered well from surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to guide treatment after surgery for stomach cancer. It uses a blood test to look for tiny pieces of cancer DNA, and then gives extra treatment only to people who still have signs of cancer. The goal is to prevent the cancer from coming back.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This trial is testing whether using a blood test to find tiny amounts of cancer DNA after initial treatment can guide decisions about further therapy for people with stomach cancer. The goal is to personalize follow-up treatment to reduce the chance of cancer returning.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This study tracks a simple blood test to look for tiny traces of cancer DNA after stomach cancer surgery. It aims to see if this test can catch any cancer coming back early, so you can get treatment sooner.
Hear when a new Gastrooesophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.